Insilica Inc. is a pioneering computational biology company building the foundational agentic infrastructure for modern biomedical discovery, evidence synthesis, and safety exploration. Supported by the NSF, NIH, and EU Horizon 2020, Insilica bridges the gap between massive, siloed scientific datasets and high-fidelity, regulatory-grade R&D.
Our mission is to accelerate safe therapeutic development, eliminate manual literature bottlenecks, and secure critical intellectual property by replacing legacy evaluation methods with deterministic, domain-specific AI agents. Engineered for the most demanding enterprise environments in pharmaceuticals and biotechnology, our platforms deploy completely within your secure VPC or air-gapped private networks, bypassing public API leaks and keeping your proprietary discoveries completely secure.
At BioTechX: